Cortexyme Acquires Novosteo to Expand Rare Bone-Disease Pipeline
May 10, 2022
Cortexyme, Inc. (Nasdaq: CRTX) has acquired privately-held Novosteo, adding Novosteo's bone-targeting therapeutic platform and lead candidate NOV004 to Cortexyme's pipeline. The deal (now closed) gives Novosteo stockholders ~15.5% of the combined company and will see Cortexyme operate under the new name Quince Therapeutics with Novosteo executives joining the leadership team.
- Buyers
- Cortexyme, Inc. (to be renamed Quince Therapeutics)
- Targets
- Novosteo, Inc.
- Industry
- Biotechnology
- Location
- Indiana, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Isto Biologics Acquires NovaBone Products LLC
August 4, 2026
Healthcare Services
Isto Biologics announced the acquisition of NovaBone Products LLC, a developer and manufacturer of synthetic bone graft products, from Halma plc. The deal, supported by Keensight Capital, adds NovaBone’s bioactive glass technologies to Isto’s bone graft substitutes platform and expands its geographic reach and surgical end-market presence.
-
Neurocrine Biosciences to Acquire Celeno Therapeutics
April 7, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.
-
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics
January 26, 2026
Healthcare Services
BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).
-
Novartis Acquires DTx Pharma
July 17, 2023
Biotechnology
Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.
-
AstraZeneca Acquires Neogene Therapeutics
November 29, 2022
Biotechnology
AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.
-
Chimerix Acquires Oncoceutics
January 7, 2021
Biotechnology
Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.